Skip to Content

Promising results for adjuvant pembrolizumab therapy in high-risk kidney cancer

Results from KEYNOTE-564 presented after the plenary session of ASCO 2021 show that adjuvant pembrolizumab therapy leads to a significant reduction in the risk of recurrence or death compared to placebo in patients with renal cell carcinoma.

Human Kidney Cross Section

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top